Literature DB >> 7859809

Using ofloxacin as a time marker in hair analysis for monitoring the dosage history of haloperidol.

M Nakano1, T Uematsu, H Sato, K Kosuge, M Nishimoto, M Nakashima.   

Abstract

Hair samples were obtained 1-5 months after ingestion of the antimicrobial ofloxacin, which had been given for 1 or 3 days at the commencement of haloperidol administration, or when its dosage was reduced. The axial distribution of ofloxacin, haloperidol and its active metabolite, reduced haloperidol, was analysed in segments from single strands of hair. Ofloxacin was detected where the content of haloperidol and reduced haloperidol along the hair shaft showed a sharp change, corresponding to the change in dose. When we matched the time scale of the dosage history to the growth rate, which was estimated using ofloxacin as the time marker, the distribution of the haloperidol and reduced haloperidol precisely coincided with the rise and fall in the dose of haloperidol. These findings demonstrate that ofloxacin can serve as a time marker when drug distribution along the hair shaft is used to obtain the drug exposure history of an individual.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7859809     DOI: 10.1007/bf00194972

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  25 in total

1.  Pathologic dynamics of human hair loss. I. Telogen effuvium.

Authors:  A M KLIGMAN
Journal:  Arch Dermatol       Date:  1961-02

2.  Human scalp hair as evidence of individual dosage history of haloperidol: longer-term follow-up study.

Authors:  T Uematsu; R Sato
Journal:  Ther Drug Monit       Date:  1990-11       Impact factor: 3.681

3.  Reference values for elements of toxicological, clinical and environmental interest in hair of urban subjects.

Authors:  O Senofonte; N Violante; L Fornarelli; E Beccaloni; A Powar; S Caroli
Journal:  Ann Ist Super Sanita       Date:  1989       Impact factor: 1.663

4.  Regeneration and rate of growth of hairs in man.

Authors:  R J MYERS; J B HAMILTON
Journal:  Ann N Y Acad Sci       Date:  1951-03       Impact factor: 5.691

5.  Clinical application of hair protein glycation in the assessment of blood glucose control and diabetic neuropathy.

Authors:  S Masuta; M Sakai; T Ohara; N Igaki; T Nakamichi; Y Maeda; F Hata; M Oimomi; S Baba
Journal:  Kobe J Med Sci       Date:  1989-02

Review 6.  Therapeutic drug monitoring in hair samples. Principles and practice.

Authors:  T Uematsu
Journal:  Clin Pharmacokinet       Date:  1993-08       Impact factor: 6.447

7.  Human scalp hair as evidence of individual dosage history of haloperidol: method and retrospective study.

Authors:  T Uematsu; R Sato; K Suzuki; S Yamaguchi; M Nakashima
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

8.  The measurement of ofloxacin in hair as an index of exposure.

Authors:  T Uematsu; N Miyazawa; M Nakashima
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

9.  Chlorpromazine in human scalp hair as an index of dosage history: comparison with simultaneously measured haloperidol.

Authors:  H Sato; T Uematsu; K Yamada; M Nakashima
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

10.  The measurement of haloperidol and reduced haloperidol in hair as an index of dosage history.

Authors:  H Matsuno; T Uematsu; M Nakashima
Journal:  Br J Clin Pharmacol       Date:  1990-02       Impact factor: 4.335

View more
  2 in total

1.  Comparative dispositions of ofloxacin in human head, axillary, and pubic hairs.

Authors:  K Kosuge; T Uematsu; S I Araki; H Matsuno; K Ohashi; M Nakashima
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

2.  The axial distribution of nicotine content along hair shaft as an indicator of changes in smoking behaviour: evaluation in a smoking-cessation programme with or without the aid of nicotine chewing gum.

Authors:  T Uematsu; A Mizuno; S Nagashima; A Oshima; M Nakamura
Journal:  Br J Clin Pharmacol       Date:  1995-06       Impact factor: 4.335

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.